story of the week
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Ineligible for Transplantation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
N. Engl. J. Med 2024 Jun 03;[EPub Ahead of Print], T Facon, MA Dimopoulos, XP Leleu, M Beksac, L Pour, R Hájek, Z Liu, J Minarik, P Moreau, J Romejko-Jarosinska, I Spicka, VI Vorobyev, B Besemer, T Ishida, W Janowski, S Kalayoglu-Besisik, G Parmar, P Robak, E Zamagni, H Goldschmidt, TG Martin, S Manier, M Mohty, C Oprea, MF Brégeault, S Macé, C Berthou, D Bregman, Z Klippel, RZ OrlowskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.